Short answer
Coherus Oncology, Inc. (CHRS) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for quarter ended September 30, 2026.
Coherus Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026
- Press release furnished as Exhibit 99.1, containing detailed financial results and management commentary
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $14.3M, up from $11.6M, while LOQTORZI revenue reached $14.0M, up 25% year over year
- Strategic reset prioritizes tagmokitug/toripalimab in esophageal cancer, while deprioritizing other indications
- Headcount reduction of approximately 30% expected to lower core cash burn by $6M to $7M quarterly over two quarters
- Second-line esophageal data showed confirmed ORR 33.3%, CBR 55.6%, and median progression-free survival 5.5 months
- Cash, equivalents, and marketable securities fell to $83.6M from $172.1M, despite planned burn reduction and $52.7M term-loan proceeds
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Coherus Oncology, Inc. 8-K filings
Get the next CHRS 8-K as it lands
Follow CHRS for push alerts, or ask the research agent what this filing means.